An orally bioavailable combination of the antimetabolite nucleoside analog TFT with the TPase inhibitor TPI; inhibits tumor growth by 65.7 and 44.9% in HCT116 and KM12C colon cancer xenograft mouse models, respectively (150 mg/kg per day for 14 days)